Day 2 of @CVCTForum #CVCT2020
Use of biomarkers in clinical trials!!!

Lawrence Fine from NIH on pros and cons of biomarkers in trials. Do they help overcome challenges and reduce sample size?
What are the best surrogate markers in trials? Bnp, TnI?
Plaque progression by #yesCCT could be one!
Charalambos Antoniades now reviews imaging endpoints in atherosclerosis and also inflammatory residual risk.
Not only plaque burden but also Fat Attenuation Index of the perivascular adipose tissue
- FAI is increased in inflammatory diseases such as psoriasis
- Statins improve FAI
- FAI restratifies individuals without high-risk plaque features
Sandra Sanders now discusses biomarkers in HF and polypharmacy

Given that BNP-guided therapy failed in GUIDE-IT trial, do we need them?
You can follow @SantosGallegoMD.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.